491 completed, 138 terminated, 126 recruiting, 114 unknown. 637 Phase 2, 305 Phase 1, 119 Phase 3, 19 Not applicable, 7 Phase 4.
Follow Cetuximab: new trials by email Literature Review of Cetuximab trials Research Report on Cetuximab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma Cemiplimab, Prednisone, Sirolimus - Kidney Transplant Recipient, Cutaneous Squamous Cell Carcinoma (CSCC) | Phase 2 | Not yet recruiting | Washington University School of Medicine | 22 | 2026-11-30 | 2026-10-15 |
| FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II) Oxaliplatin, 5-Fluorouracil, Levofolinic Acid For Injection - Metastatic Colorectal Cancer (CRC) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 229 | 2026-11-01 | 2026-10-16 |
| Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma Cetuximab, Cemiplimab - Locally Advanced Cutaneous Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Melanoma and Skin Cancer Trials Limited | 27 | 2026-10-30 | 2026-10-07 |
| IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors IL-12 GEMys, Cyclophosphamide, Fludarabine - Relapsed Solid Tumor Malignancies, Refractory Solid Tumor Malignancies | Phase 1 | Recruiting | National Cancer Institute (NCI) | 95 | 2026-10-27 | 2026-10-22 |
| Iparomlimab and Tuvonralimab With With Cetuximab in Resectable OSCC iparomlimab and tuvonralimab combined with cetuximab - Head and Neck Cancer | Phase 2 | Recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 26 | 2026-10-16 | 2026-10-20 |
| A Prospective, Single-Arm, Multicenter, Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) Combined With Cetuximab and mFOLFIRI Regimen as First-Line Treatment for Recurrent or Metastatic Colorectal Cancer QL1706 combined with cetuximab and mFOLFIRI - Colorectal Cancer | Not applicable | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 55 | 2026-10-08 | 2026-10-14 |
| Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2) Petosemtamab, Cetuximab, Bevacizumab - Colorectal Cancer | Phase 3 | Recruiting | Genmab | 600 | 2026-10-07 | 2026-10-09 |
| Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients FOLFIRI+cetuximab, Guardant360 ctDNA assay - Colorectal Cancer Metastatic | Phase 3 | Not yet recruiting | Charite University, Berlin, Germany | 267 | 2026-10-01 | 2026-07-29 |
| A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation Olomorasib, Cetuximab, Oxaliplatin - Colorectal Neoplasms | Phase 2 | Not yet recruiting | Eli Lilly and Company | 50 | 2026-10-01 | 2026-10-15 |
| A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma CRB-701, capcitabine, Cetuximab (EGFR inhibitor) - Oropharyngeal Carcinoma (OPC) | Phase 3 | Recruiting | Corbus Pharmaceuticals Inc. | 260 | 2026-09-29 | 2026-10-08 |
| Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status Cetuximab (EGFR inhibitor), Bevacizumab, Irinotecan (CPT-11) - Colorectal Cancer | Phase 4 | Not yet recruiting | Gruppo Oncologico del Nord-Ovest | 280 | 2026-09-15 | 2026-07-24 |
| A Randomized, Double-Blind, Positive-Controlled, Parallel Pharmacokinetic Phase I Clinical Study of Cetuximab Injection Versus Erbitux in Healthy Male Subjects HC034S, Erbitux (Cetuximab) - Cetuximab, Bioequivalence | Phase 1 | Recruiting | HC Biopharma Inc. | 92 | 2026-09-05 | 2026-09-10 |
| A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations BG-85738, Tislelizumab, Cetuximab - RAS Mutation, Advanced Solid Tumor | Phase 1 | Recruiting | BeOne Medicines | 100 | 2026-09-02 | 2026-09-11 |
| A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation GFH276, Cetuximab, Nab paclitaxel - Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Genfleet Therapeutics (Shanghai) Inc. | 222 | 2026-09-01 | 2026-10-05 |
| Open-Label Neoadjuvant Pembrolizumab Plus Cetuximab in Betel Nut-Associated Locally Advanced Oral Cavity Squamous Cell Carcinoma Pembrolizumab and cetuximab - Betel-nut-associated Oral Carcinoma | Phase 2 | Not yet recruiting | Peter Brett, MD | 20 | 2026-08-15 | 2026-08-10 |
| HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer HSK42360-Na Tablets, Cetuximab (EGFR inhibitor), mFOLFOX6 Regimen (Oxaliplatin/Leucovorin/5-FU) - Metastatic Colorectal Cancer (CRC) | Phase 1 / Phase 2 | Recruiting | Haisco Pharmaceutical Group Co., Ltd. | 180 | 2026-08-12 | 2026-08-27 |
| Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1) Petosemtamab, Cetuximab, FOLFIRI - Left-sided Colorectal Cancer | Phase 3 | Recruiting | Genmab | 960 | 2026-08-11 | 2026-10-06 |
| Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors NK Cells, NK cells + PD-(L)1 inhibitor + pemetrexed as first-line maintenance therapy, NK cells + cetuximab/bevacizumab + capecitabine as first-line maintenance therapy - NSCLC (Advanced Non-small Cell Lung Cancer), Colorectal Cancer | Phase 1 / Phase 2 | Not yet recruiting | BOE Technology Group Co., Ltd. | 42 | 2026-08-01 | 2026-08-26 |
| Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin Biospecimen Collection, Carboplatin, Cetuximab - Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 454 | 2026-07-31 | 2026-08-17 |
| A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer VS-7375, cetuximab, panitumumab - Colorectal Cancer | Phase 2 | Recruiting | Verastem, Inc. | 150 | 2026-07-28 | 2026-10-21 |
Showing 20 of 980. Sign in to see all of them.
Colorectal Neoplasms (326) · Squamous Cell Carcinoma of Head and Neck (171) · Head and Neck Neoplasms (152) · Carcinoma, Non-Small-Cell Lung (97) · Colonic Neoplasms (92) · Rectal Neoplasms (83) · Neoplasm Metastasis (75) · Neoplasms (60) · Pancreatic Neoplasms (43) · Carcinoma, Squamous Cell (40) · Lung Neoplasms (36) · Esophageal Neoplasms (25) · Breast Neoplasms (22) · Recurrence (21) · Stomach Neoplasms (20)
Eli Lilly and Company (46) · National Cancer Institute (NCI) (38) · M.D. Anderson Cancer Center (31) · Merck KGaA, Darmstadt, Germany (30) · Memorial Sloan Kettering Cancer Center (19) · Fudan University (18) · Merck Sharp & Dohme LLC (16) · Sun Yat-sen University (15) · Bristol-Myers Squibb (14) · Pfizer (13) · Alliance for Clinical Trials in Oncology (11) · Washington University School of Medicine (11) · Dana-Farber Cancer Institute (10) · Groupe Oncologie Radiotherapie Tete et Cou (10) · Hoffmann-La Roche (10)
United States (502) · France (138) · China (135) · Spain (112) · Italy (104) · Germany (89) · Canada (75) · South Korea (73) · United Kingdom (73) · Australia (69) · Belgium (62) · Netherlands (51) · Japan (45) · Taiwan (42) · Austria (41)
Douglas Adkins, M.D. (7) · Tanguy Seiwert (4) · Ari Rosenberg, MD (3) · Barbara A. Burtness, MD (3)
PMID 25057165, PMID 16467544, PMID 19339720, PMID 19897418, PMID 23265711, PMID 27722750, PMID 28797458, PMID 30466310, PMID 30944020, PMID 31268130, PMID 33356421, PMID 33684371, PMID 36306483, PMID 36763936, PMID 36852723, PMID 36880426, PMID 38592721, PMID 40215447, PMID 41343184, PMID 10493478, PMID 10744089, PMID 11208820, PMID 11247898, PMID 12518365, PMID 12927569, PMID 14967461, PMID 15142632, PMID 15175435, PMID 1584260, PMID 15870084, PMID 15908664, PMID 16246975, PMID 16314626, PMID 16356309, PMID 16476835, PMID 16681848, PMID 16943526, PMID 17050875, PMID 17470860, PMID 17553204, PMID 17704420, PMID 17960012, PMID 17960013, PMID 18003960, PMID 18077217, PMID 18191993, PMID 18272912, PMID 18279058, PMID 18316791, PMID 18349029
2023 (13), 2009 (12), 2025 (10), 2014 (9), 2015 (9), U10CA032102 (9), 2008 (7), U10CA021115 (7), 2016 (6), 2017 (6), 2019 (6), U10CA180888 (6), P30CA068485 (5), 2018 (4), N01CM62201 (4)